ABT Earnings

To the extent required to avoid accelerated taxation and/or tax penalties under Code Section 409A and applicable guidance issued thereunder, the Employee shall not be deemed to have had a Termination unless the Employee has incurred a “separation from service” as defined in Treasury Regulation §1.

5 To the extent required to avoid accelerated taxation and/or tax penalties under Code Section 409A and applicable guidance issued thereunder, the Director shall not be deemed to have had a Termination unless the Director has incurred a “separation from service” as defined in Treasury Regulation §1.

es, establishing Abbott as a leader in the fast-growing oncology diagnostics market – Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5% 1 – Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences ABBOTT PARK, Ill.

sition of Exact Sciences, establishing the company as a leader in the oncology diagnostics market and adding a new high-growth vertical to Abbott's portfolio. • Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5% 1 . • Abbott projects full-year 2026 adjusted diluted EPS of $5.

Page 6 of 15 Abbott's Financial Guidance Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%. Abbott projects full-year 2026 adjusted diluted earnings per share of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.